Kiora Pharmaceuticals logo

Kiora PharmaceuticalsNASDAQ: KPRX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

13 February 2015

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$9.99 M
-35%vs. 3y high
18%vs. sector
-vs. 3y high
-vs. sector
-29%vs. 3y high
21%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Thu, 21 Nov 2024 21:41:10 GMT
$3.33-$0.07(-2.06%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

KPRX Latest News

Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies
newsfilecorp.com08 November 2024 Sentiment: POSITIVE

Encinitas, California--(Newsfile Corp. - November 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2024 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key third quarter and recent corporate highlights include: Investigational new drug application approval to initiate ABACUS-2, the Phase 2 study of KIO-301, a novel molecular photoswitch, for the treatment of retinitis pigmentosa.

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences
newsfilecorp.com06 August 2024 Sentiment: POSITIVE

Encinitas, California--(Newsfile Corp. - August 6, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in two upcoming conferences that will be available to investors by live webcast. On Tuesday August 13th, 2024 at 3:00 pm Eastern Time, Kiora's President and CEO, Brian Strem, Ph.D.

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors
newsfilecorp.com01 July 2024 Sentiment: POSITIVE

Ken Gayron to Step Down as a Member of the Company's Board Encinitas, California--(Newsfile Corp. - July 1, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that it has appointed Lisa Walters-Hoffert as an independent member to the Company's Board of Directors. Ms. Walters-Hoffert is a seasoned biotech executive bringing decades of experience in strategic development, governance, finance and capital markets to the Company's Board.

Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board
newsfilecorp.com25 June 2024 Sentiment: POSITIVE

Encinitas, California--(Newsfile Corp. - June 25, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed Roger A. Goldberg, MD, MBA, a vitreoretinal surgeon at Bay Area Retina Associates (BARA) to its Scientific Advisory Board.

Why Is Kiora Pharmaceuticals (KPRX) Stock Up 39% Today?
InvestorPlace01 February 2024 Sentiment: POSITIVE

Kiora Pharmaceuticals (NASDAQ: KPRX ) stock is heading higher on Thursday after the clinical-stage specialty pharmaceutical company announced a $45 million private placement. According to a press release from Kiora Pharmaceuticals, the company has entered into a financing agreement with healthcare-focused institutional investors.

Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference
Newsfile Corp16 October 2023 Sentiment: POSITIVE

Encinitas, California--(Newsfile Corp. - October 16, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation from the Lytham Partners Fall 2023 Investor Conference taking place on Tuesday October 17, 2023. As part of the presentation, Melisa Tosca, CPA, Kiora's Executive Vice President of Finance, will provide an overview of the Company's business and clinical development pipeline for inherited retinal diseases.

Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa
Newsfile Corp14 September 2023 Sentiment: POSITIVE

Encinitas, California--(Newsfile Corp. - September 14, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that results from the ABACUS study of KIO-301 in patients with late-stage retinitis pigmentosa will be presented at the American Academy of Ophthalmology (AAO 2023) conference on November 4, 2023. The late-breaking abstract has been accepted for presentation at the retinal subspecialty day and will include findings from all six participants and 12 evaluated eyes in the Phase 1b, dose-escalating, open-label study.

Why Is Kiora Pharmaceuticals (KPRX) Stock Up 11% Today?
InvestorPlace23 August 2023 Sentiment: POSITIVE

Kiora Pharmaceuticals (NASDAQ: KPRX ) stock is getting a boost on Wednesday after the company revealed new patents in the U.S. and Europe. According to a press release from Kiora Pharmaceuticals, these patents cover the “local ocular delivery of the KIO-100 family of non-steroidal, anti-inflammatory small molecules.

Why Is Kiora Pharmaceuticals (KPRX) Stock Down 7% Today?
InvestorPlace21 July 2023 Sentiment: NEGATIVE

Kiora Pharmaceuticals (NASDAQ: KPRX ) stock is dropping on Friday after the clinical-stage pharmaceutical company received a delisting notice. That delisting notice comes from the Listing Qualifications Department of the Nasdaq Capital Market.

Why Is Kiora Pharmaceuticals (KPRX) Stock Down 49% Today?
InvestorPlace02 June 2023 Sentiment: NEGATIVE

Kiora Pharmaceuticals (NASDAQ: KPRX ) stock is falling hard on Friday after the company revealed details of a public share offering. The offering has Kiora Pharmaceuticals selling 1,447,628 shares of KPRX stock.

What type of business is Kiora Pharmaceuticals?

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials indicated for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, currently under phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; KIO-101, an eye drop for the treatment of ocular presentation of rheumatoid arthritis; and KIO-201, an eye drop for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. It has commercialization agreement with 4SC Discovery GmbH, for KIO-101; and collaboration agreement with Théa Open Innovation for the development KIO-301. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

What sector is Kiora Pharmaceuticals in?

Kiora Pharmaceuticals is in the Healthcare sector

What industry is Kiora Pharmaceuticals in?

Kiora Pharmaceuticals is in the Biotechnology industry

What country is Kiora Pharmaceuticals from?

Kiora Pharmaceuticals is headquartered in United States

When did Kiora Pharmaceuticals go public?

Kiora Pharmaceuticals initial public offering (IPO) was on 13 February 2015

What is Kiora Pharmaceuticals website?

https://www.kiorapharma.com

Is Kiora Pharmaceuticals in the S&P 500?

No, Kiora Pharmaceuticals is not included in the S&P 500 index

Is Kiora Pharmaceuticals in the NASDAQ 100?

No, Kiora Pharmaceuticals is not included in the NASDAQ 100 index

Is Kiora Pharmaceuticals in the Dow Jones?

No, Kiora Pharmaceuticals is not included in the Dow Jones index

When was Kiora Pharmaceuticals the previous earnings report?

No data

When does Kiora Pharmaceuticals earnings report?

Next earnings report date is not announced yet